Aml antigens and uses thereof

Abstract

The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.

1 . A synthetic or recombinant nucleic acid molecule, or a functional equivalent thereof, encoding a CD43 peptide for AT14-013 antibody binding, said peptide comprising the amino acid sequence of SEQ ID NO. 3 and having an AML-specific glycosylation pattern or an MDS-specific glycosylation pattern. 
     
     
         2 . The nucleic acid molecule or functional equivalent of  claim 1 , wherein said nucleic acid molecule or functional equivalent has been codon optimized for a non-human cell, for instance for a non-human producer cell. 
     
     
         3 . The nucleic acid molecule or functional equivalent of  claim 1 , wherein said nucleic acid molecule or functional equivalent comprises a chain comprising non-natural nucleotides, modified nucleotides and/or non-nucleotide building blocks which exhibit the same function as natural nucleotides. 
     
     
         4 . The nucleic acid molecule or functional equivalent of  claim 1 , wherein said nucleic acid molecule or functional equivalent comprises a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme. 
     
     
         5 . The nucleic acid molecule or functional equivalent of  claim 1 , wherein said nucleic acid molecule or functional equivalent comprises cDNA. 
     
     
         6 . A vector comprising the nucleic acid molecule or functional equivalent of  claim 1 . 
     
     
         7 . A method for producing, binding, detecting and/or obtaining an immune cell and/or an antibody, or a functional part or functional equivalent thereof, characterized in that a nucleic acid molecule or functional equivalent of  claim 1  is used. 
     
     
         8 . The method of  claim 7 , for inducing, binding, detecting and/or obtaining an immune cell and/or an antibody, or a functional part or functional equivalent thereof, that is able to specifically bind myeloproliferative or lymphoproliferative cells. 
     
     
         9 . The method of  claim 8 , wherein said myeloproliferative cells are acute myeloid leukemia (AML) cells or myelodysplastic syndrome (MDS) cells or chronic myeloid leukemia (CML) cells. 
     
     
         10 . The method of  claim 7 , wherein said antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) inducing activity and/or complement-dependent cytotoxicity (CDC). 
     
     
         11 . A gene delivery vehicle comprising the nucleic acid molecule or functional equivalent of  claim 1 . 
     
     
         12 . A host cell comprising the nucleic acid molecule or functional equivalent of  claim 1 .